Abstract

Following the approval of the first direct-acting antiviral in 2011, an unforeseen revolution in the treatment of chronic hepatitis C has taken place. Sustained virological response rates have risen to 90–95% in clinical trials. Will these results be reproduced in clinical practice? Will more difficult-to-treat patient populations continue to exist in the era of all-oral direct-acting antiviral therapy?